REQUEST FOR PROPOSAL

UNDER CLOSED FRAME WORK OF AGREEMENT FROM PREQUALIFIED FIRMS

(DRUGS/MEDICINES IN BULK)

(FINANCIAL YEAR 2025-26)

FEDEAL GOVERNMENT POLYCLINIC

(Post Graduate Medical Institute)

Islamabad

RFP DATA SHEET

Description	Detail
Last date and time for the receipt of bids	LAST DATE FOR RFP SUBMISSION 15-12 -2025 TILL 11:00 A.M
Date, time and venue of opening of technical bids	DATE 15 -12-2025 AT 11:30 A.M **VENUE:** Auditorium of FGPC
RFP/Bid Reference No. (Drugs / Medicines)	Drug & Medicine For FY 2025-2026 (Extendable)
Bid currency	PKR on free delivery to FGPC
Language of bid	English
Amount of bid security	**3.00 Million (Pkr)**
Bid validity period	180 days from the date of the submission of bids
Bidding procedure	Closed Frame work agreement with prequalified bidders under Single Stage – Two Envelope bidding procedure
Federal Government Polyclinic (PGMI) Hospital, Sector G 6/2, Islamabad Tel: +92519218300-8	

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

LETTER OF INVITATION

M/s Popular International (Pvt) Ltd,
F-880, Satellite Town,
Rawalpindi,

M/s Chiesi Pharmaceuticals
Office No. 04, 4th floor, Askari Corporate Tower,
75/76-D-1, Main Boulevard, Gulberg-III
Lahore

M/s Al- Waqar Trading Co,
312.G.H.I, Aziz Mansion, RA Bazar,
Rawalpindi Cantt.

M/s. Allons Enterprises,
House F-798, Block-F
Satellite Town. **Rawalpindi**

M/s Chaudhary Pharma
Plot NO.14, C.P Tower,
Street No.17, Korang Town Ext,
Islamabad.

M/s Med-n-Tec Pharma
D-574, Satellite town,
Rawalpindi

SUBJECT**: INVITATION OF REQUEST FOR PROPOSALS UNDER CLOSED FRAME WORK OF AGREEMENT ACCORDING TO RULE 36(b) OF PPRA RULES 2004 FOR DRUGS & MEDICINES IN BULK PURCHASEFORTHE FINANCIAL YEAR 2025-26 FROM PREQUALIFIED FIRMS.**

Dear Sir/ Madam

Executive Director, Federal Government Polyclinic (PGMI), Islamabad invites sealed RFP(Technical& Financial under PPRA Rule 36 (b) PPRA Rules 2004 (closed frame work of agreement)for the supply of Drugs& Medicines in bulk purchase from prequalified firms/bidders for the FY **2025-26** (extendable till finalization of next tender) to Federal Government Polyclinic (FGPC). Only pre-qualified Pharmaceutical Manufacturing Units, Marketing Authorization Holder/Importer/ Indenter (Sole Agents in case of imported drugs) and Authorized Distributors are eligible to participate in this process. The list of drugs & Medicines along with tentative quantities is given in the RFP Documents.

2. All prequalified firms must participate in the bidding process for the items against the list provided at **Annex-I** (which was also provided with the prequalification documents)

3. It is pertinent to mention that no change in authorization will be accepted against the authorization for which the firm is already prequalified. In such case bidder/prequalified firm, status of prequalification will be cancelled immediately till the extend of that manufacturer by the Executive Director and notification will be issued accordingly.

4. Prequalified Bidders can download the RFP Documents containing tender's item tentative quantity, terms & conditions from the EPADS of PPRA.

4. Bidding process shall be conducted through Single Stage – Two Envelopes bidding procedure under 36 (b) of PPRA Rules, 2004. (Closed frame work of agreement) The envelopes shall be marked as "**FINANCIAL PROPOSAL"** and **TECHNICAL PROPOSAL**" in bold and legible letters. The outer envelope shall clearly be **marked with Tender for Purchase of Drugs and Medicines in bulk**. Financial Proposal of bids, which are found technically non-responsive shall be returned un-opened to the respective bidder/s. **It is advised that Technical &financial proposal/s should be submitted separately for quoted item/s.**

5. **It is Mandatory to submit the bid on EPADS of PPRA failing which no bid will be entertained.**

6. The last date and time for bid submission is 15 /12 **/2025 up till 11:00 a.m which** shall be opened on the same date at **11:30 a.m**.

7. All documents should contain proper page marking, attached in sequence as indicated for evaluation in the RFP Documents and signatures of authorized person. Moreover, signing and stamping of each page of bidding documents/form may be made.

8. In case the date of opening is declared as a public holiday by the government or non-working day due to any reason, the next official working day shall be deemed to be the date of submission and opening of tenders accordingly. The time and venue shall remain the same.

Note:

1) **The Procurement/Bidding Process shall be governed by the PPRA rules 2004.**

2) **Item(s) shall be quoted in Technical & Financial Proposal with both Brand Name(s) and generic name.**

3) The prequalified bidder will submit call deposit initially **Rs.3.0 million (Pkr)** as bid security in favour of Executive Director FGPC along with bid documents **in the form of Bank Draft/Call Deposit Receipt(CDR)/Pay order, with Technical Proposal clearly showing the amount (Photo copy) and original with Financial Proposal.**

4) After the issuance of intent letter the supplier will replace the call at **deposit/CDR @ 5%** performance guarantee of total amount of the awarded items.

EXECUTIVE DIRECTOR
Federal Government Polyclinic (PGMI),
Islamabad

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

TERMS & CONDITIONS AND SCHEDULE FOR PURCHASE OF DRUGS/MEDICINESIN BULK FROM PRE-QUALIFIED PHARMACEUTICAL MANUFACTURING UNITS, MARKETING AUTHORIZATION HOLDER/IMPORTER/ INDENTER (SOLE AGENTS) IN CASE OF IMPORTED DRUGS AND AUTHORIZED DISTRIBUTORSFOR FEDERAL GOVT. POLYCLINIC, (PGMI) ISLAMABAD FOR THE FINANCIAL YEAR 2025-26 (EXTENDABLE)

Tender bid will be received before 11.00AM on opening date.
Tender will be opened on 15-12 -2025 11:30 AM

INSTRUCTIONS TO PREQUALIFIED BIDDERS

1.	Executive Director, Federal Government Polyclinic (PGMI), Islamabad, invites sealed bids from **Prequalified** Pharmaceutical Manufacturing Units, Marketing Authorization Holder/Importer/ Indenter (Sole Agents in case of imported drugs) and Authorized Distributors for supply of Drugs & Medicines for Federal Government Polyclinic (PGMI), hospital, Islamabad as per tentative quantities, more specifically described in **Annex-I** of the RFP Documents i.e. List of Drug & Medicines along with estimated quantity.
2.	i. The Marketing Authorization Holder/Importer/ Indenter (Sole Agents)must possess valid authorization from the Manufacturer as well as Drug Sale License (DSL). ii. In case of Manufacturer, they should have a documentary proof as prescribed in Bidding documents that they are the original Manufacturer of the required specifications of Goods. iii. In case of Authorized Distributor they should have valid Drug sale license (DSL) and Authorization letter of each firm, items of which are quoted.
3.	Bidders under a declaration of ineligibility for corrupt and fraudulent practices issued by any Government (Federal and Provincial) or a Public-sector organization are not eligible to participate in the bidding process.
	(a) In pursuance to this, the terms as defined in Clauses 2 (b)(f) & 19 of PPRA rules 2004
	(b) Executive Director FGPC, will reject a proposal for Prequalification under PPRA Rule 33, if it determines that the applicant has directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the Prequalification in question
	(c) Procuring Agency will also declare the Applicant as blacklisted in accordance with Public Procurement Rule 19 and predefined standard mechanism.
4.	In case of non-compliance of services, bidder will be black listed as per PPRA rules 2004.
5.	All **Prequalified** Pharmaceutical Manufacturing Units, Marketing Authorization Holder/Importer/ Indenter (Sole Agents) in case of imported drugs and Authorized Distributorsare eligible for the bidding procedure.
6.	All goods and related services to be supplied under the contract shall conform to the policies of the Federal Government in vogue.
7.	The Bidder shall bear all costs associated with the preparation and submission of its bid and the Procuring Agency shall in no case be responsible or liable for those costs, regardless of the conduct or outcome of the bidding process.
8.	A Bidder can bid for selective items OR all items from the list of drugs and medicines provided in the **Annex-I** of the RFP Documents(List of Drug & Medicines along with estimated/tentative quantity)
9.	The bid must be for the item/s required in the attached list at **Annex-I** of the RFP Documents (List of Drug & Medicines along with estimated quantity)
10.	A Prequalified Bidder requiring any clarification(s) on the Bidding Documents may approach the Procuring Agency through EPADS of PPRA vide its "clarification section". The Procuring Agency shall respond to the same clarification(s) through EPADS, only if received within **Ten (10) days** after publication/ advertisement of notice (Closed framework of agreement). No clarification will be addressed after 10 days of advertisement.

11.	All prequalified Authorized Distributors and Sole Agents are not allowed to change any distribution/ authorization against which they are already prequalified. If any discrepancy is found regarding change of distribution/ authorization from the documents of prequalification, the items of that distribution will not be accepted and will not be considered in technical evaluation.

INSTRUCTIONS FOR FILLING OF THE CONTRACT DOCUMENTS

01.	The participant firms are directed to submit **their bids on-line through EPADS of PPRA which is mandatory, failing which the bids will not be entertained.** The hard copies (**Technical Bid and Financial Bid**) will be submitted in FGPC with proper page marking and proper binding shape. The competent authority reserves the right to cancel their bids under 33(1) of PPRA Rules 2004.
02.	**Vendors are not allowed to change FGPC tender Schedule/Financial bid serial numbers/ specifications**.
03.	All vendors are requested to submit their quotations/financial bids in form of computerized print only. Bids which are hand written, typed on manual typewriter andtyped on electronic typewriter shall not be accepted and same will be rejected at the time of tenders opening without any notice.
04.	Erasing, overwriting and miss-calculation is liable to rejection of bid or relevant item/s. However, Chairman Technical/Financial Committee will be final authority according to the ground situation.
05.	The participant Vendors/firms are requested to provide the Soft copy in USBof their offered bids along with hard copy in addition to EPADS submission.
06.	The participant bidder will provide the copy of price list of quoted products (issued by the DRAP),where applicable.
07.	**Closed framework agreement documents can be downloaded from EPADS of PPRA.**
08.	**Participants are directed to attach photocopy of Pay Order/CDR as per prescribed amount with technical bid and attach original Pay Order/CDR with financial bid. The original pay order/CDR on EPADS should be same as the hard copies of pay order/CDR attached with technical & financial bid.**
09.	**The participant/bidder may submit/quote their rates in Financial proposal as per proforma tabulated as under:-**

Tender. S.No	Generic Name	Brand Name	Strength (where applicable)	Packing size (where applicable)	Quoted pack Price	Quoted Unit Price	Retail Price	DRAP Reg. #	Manufacturer/ Marketed by

10.	**The provided bid/s (Technical &Financial) in the form of hard copy and EPADS of PPRA may be duly signed& stamped on each page and sealed thereof. Documents submitted in hard copy as well as on EPADS of PPRA should be same, however documents submitted on EPADS will be considered final for evaluation.**

Note: **No Grievance/s will be entertained regarding Technical & Financial evaluation on bid opening date. Grievance/s received through EPADS only will be entertained. Grievance/s received in written/hard form will be rejected.**

Issued to M/s ……..……..…..

Vide receipt No……..…..… dated……..

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

SINGLE STAGE-TWO ENVELOPE PROCEDURE UNDER CLOSED FRAME WORK OF AGREEMENT FROM PREQUALIFIED FIRMS/BIDDERS.

1. The bid shall comprise a single package containing two separate envelopes. Each envelope shall contain separately the financial proposal and the technical proposal.

2. The envelopes shall be marked as "**TECHNICAL PROPOSAL**" and **FINANCIAL PROPOSAL**" in bold and legible letters to avoid confusion.

3. Initially, only the envelope marked **"TECHNICAL PROPOSAL**" shall be opened.

4. The envelope marked as "**FINANCIAL PROPOSAL**" shall be retained in the custody of the procuring agency without being opened.

5. The procuring agency shall evaluate the technical proposal in a manner prescribed in advance, without reference to the price and reject the proposal which do not conform to the specified requirements.

6. During the technical evaluation no amendments in the technical proposal shall be permitted.

7. The financial proposals of bids shall be opened publically at a time, date and venue announced and communicated to the bidders in advance.

8. After the evaluation and approval of the technical proposal the procuring agency, shall at a time within the bid validity period, publically open the financial proposals of the technically accepted bids only. The financial proposal of bids found technically non-responsive shall be retuned un-opened to the respective bidders.

9. The bid found to be the lowest and most advantageous evaluated bid shall be accepted.

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

REQUEST FOR PROPOSALS UNDER CLOSED FRAME WORK OF AGREEMENT ACCORDING TO RULE 36(b) OF PPRA RULES 2004 FOR DRUGS & MEDICINES IN BULK PURCHASEFOR THE FINANCIAL YEAR 2025-26 FROM PREQUALIFIED FIRMS/BIDDERS.

TECHNICAL OFFER/CHECK LIST 2025-26

The following documents are mandatory to submit along with tender for annual tender for supply of drugs/medicines in bulk for the financial year 2025-26.

S.#	Detail of Documents	Compliance Status Yes / No	Page #
1.	Name of the Firm, Postal Address Telephone Number, Cell No.Fax # and Email address.		
2.	Name, Designation & specimen signature of concerned person/ focal person, CNIC No. of the concerned person		
3.	Active GST certificate & Active NTN.		
4.	Copy of CDR amounting **Rs. 3.00 Million (Three hundred thourand) PKR**		
5.	Firm is prequalified for supply of drugs/medicines in bulk for the financial year 2025-26 in FGPC		
6.	i. The Marketing Authorization Holder/Importer/ Indenter (Sole Agents) must possess valid authorization from the Manufacturer as well as Drug Sale License (DSL). ii. In case of Manufacturer, they should have a documentary proof as prescribed in Bidding documents that they are the original Manufacturer of the required specifications of Goods. iii. In case of Authorized Distributor they should have valid Drug sale license (DSL) and Authorization letter of each firm, items of which are quoted.		
7.	Valid drug registration of quoted drug by DRAP.		

INSTRUCTIONS TO FILL TECHNICAL EVALUATION PERFORMA.

- The bidder shall fill this checklist carefully & attach the relevant documents in the same Sequence as prescribed in the bid form.
- All the undertaking/affidavit must be on judicial paper (in original).
- All the documents attached must be attested/signed & stamped on behalf of firm.
- All the documents of bid shall be affixed **with number.**
- **Page number** of attached document against every evaluation criteria must be mentioned in the specified column.

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

DRUG/MEDICINES 2025-26

ITEM WISE TECHNICAL EVALUATION CRITERIA OF SCORING

It will be carried out by Technical Evaluation Committee constituted by Executive Director, FGPC consisting of all HODs/ Senior Consultants of the available Specialties, Chief Pharmacist, representatives from M/o NHSR&C and administration of FGPC. The Committee will evaluate the bids in the light of required specifications and documents submitted. The Committee shall be empowered to recommend suitable and appropriate brands / strength in the interest of patient as per given technical evaluation chart:

NOTE: ***Valid drug registration certificate with DRAP is mandatory for evaluation/ scoring of items, failing which it will not be technically considered/scored/approved despite fulfilling all other criteria/s.***

		Total Score:100 **Passing Score:70**	
S.No	**DESCRIPTION**	**WEIGHTAGE**	**SCORE ACHIEVED**
A.	**QUALITY**	**0 to 45**	
A-1	Valid drug registration certificate with DRAP.	0 or 10	
A.2	Original Research Product	0 or 05	
A-3	Quality Testing Report of quoted product during last three (03) years from Drug Testing Laboratories of Pakistanand in case of imported product (Registered with DRAP) the testing/analysis report of any International /ISO certified Laboratory.	0 or 10	
A-4	i. The Marketing Authorization Holder/Importer/ Indenter (Sole Agents) must possess valid authorization from the Manufacturer as well as Drug Sale License (DSL). ii. In case of Manufacturer, they should have a documentary proof as prescribed in Bidding documents that they are the original Manufacturer of the required specifications of Goods. iii. In case of Authorized Distributor they should have valid Drug sale license (DSL) and Authorization letter of each firm, items of which are quoted.	0 or 05	
A-5	Bioequivalence/Pharmacokinetics/Pharmaco-dynamics report from any international/ISO certified Laboratory	0 or 10	
A-6	Active Pharmaceutical Ingredient (Drug Raw material) is FDA approved with certificate of analysis. *(The bidder will undertake on Rs.100/- notarized stamp paper that it will provide the supply manufactured from claimed source.)*	0 or 05	
B.	**EXPERIENCE**	**0 to 10**	
B-1	End-user experience with desired clinical response, previous use in FGPC or beyond in light of their clinical experience.	0 to 10	
C.	**SAFETY AND SUPPLY CHAIN INTEGRITY**	**0 to 10**	
C.1	Undertaking on judicial paper (Rs. 100) that no adverse events of quoted drug/sis reported during last three years i.e,2022-23, 2023-24 & 2024-25.	0 or 5	
C-2	Undertaking on judicial paper (Rs. 100) mentioning that the quoted drug/s is Bio-safe and in well differentiable packaging.	0 or 5	
D.	**MANUFACTURING**	**0 to 10**	
D-1	Manufacturing,packaging and marketing of medicine By firm itself = 10 By the 3rd party = 05 Firm will submit an undertaking on their letter head clearly mentioning each quoted product, whether its manufacturer is preparing/packaging the drug by itself or through 3rd party.	05 or 10	
E.	**MARKET STANDING/SERVICES**	**0 to 20**	
E-1	Duration of availability of quoted brand in open market. Duration of quoted brand will be assessed from the date of registration with DRAP. (Documentary Proof of DRAP Registration) **Scoring Guide** 01 to 02 years =02 Above 02 to 05 years =03 Above 05 years =05 In case document not provided or experience is less than one year it will be scored Zero.	0 to 05	

E-2	• History of services regarding timely and full supplies in stores of FGPC. • In case of new supplier to FGPC, with provision of good experience certificate, five (05) marks will be given and if good experience certificate is not available, zero marks will be given. *(In case of new suppliers, bidder will submit good standing experience of last 05 years clearly showing that regular supplies were given and no show cause/ warning was made against the firm. The good standing experience should be issued from those public sector hospitals which are mentioned at time of prequalification).*	0 to 10	
E-3	Active IMS data documentary proof	0 or 05	
F.	Undertaking on judicial paper (Rs. 100) that the firm/ bidder will ensure supply of the quoted products with **BAR-CODING.**(where applicable)	**0 or 5**	
	TOTAL:-	**100**	

The Technical Committee will evaluate and recommend the quoted item/s of prequalified Firms. The recommendations of Technical Committee will be submitted to Competent Authority for approval, before opening of Financial Bids.

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

DETAIL OF QUOTED PRODUCTS.

Tender. S.No	Generic Name	Brand Name	Strength (where applicable)	Packing size (where applicable)	Quoted pack Price	Quoted Unit Price	Retail Price	DRAPReg. #	Manufacturer/ Marketed by

Signature and Stamped of authorized person of Firm/supplier.

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

Instructions/terms & conditions for supply of Drugs/Medicines (Bulk Purchase) on annual contract under closed frame work of agreement for the financial year 2025-26 (Extendable)

	A. INSTRUCTIONS FOR FILLING OF THE CONTRACT DOCUMENTS:-
1.	Sealed tender **Single stage +Two envelop procedure as per PPRA rules 2004, (36)(b)" Under closed frame work of agreement"** is to be submitted by prequalified firms/bidders in the name of FGPC before the stipulated date and time of opening(as per tender advertisement). It will be dropped in the sealed tender box by hand as well as be submitted on the EPADS of PPRA. **Bid not received on EPADs of PPRA will not be entertained in hard form at FGPC and will be considered as rejected**.
2.	The Vendor/s currently **under litigation with FGPC** is not eligible to participate in the tender process.
3.	The item/s are to be quoted on given Proforma duly filled-in, stamped and signed by the authorized representative of Firm. No other Proforma for tender will be accepted. Only those items shall be typed on the Proforma for which the rates are quoted.
4.	The Vendors/firms are not allowed to change the Serial No. and specification/s of tender schedules after the submission of documents. **In case of non-compliance, complete bid or item/s will be cancelled by the Chairman (Technical/Financial) Committee.**
5.	The participant Vendors/firms are required to provide the Soft copy in form of USB along with hard copy.
6.	Any conditional, ambiguous or incomplete offer in any respect shall be cancelled. No supplementary or revised offer after the opening of tender shall be entertained. Any clarification required by the technical committee will be published on EPADS.
7.	In case a firm is quoting two or more brands of the same item/s, the bidder is requested to mention each brand in separate lines with same tender serial number. The firms quoting the rates of two or more brands of same item in one line/column are liable to be rejected.
8.	The prequalified bidder will submit call deposit (**CDR**) initially **Rs. 3,000,000/-(Three Million)** in favour of Executive Director FGPC, along with bid documents. After the issuance of intent letter, the supplier will replace the call at **deposit/CDR with a 5%** performance guarantee of total amount of the awarded items. **(CROSS CHEQUE/OPEN CHEQUE NOT ACCEPTABLE).**The performance guarantee will be released on rejection of tender or completion of successful contract (after issuance of NOC from concerned Store).
9.	Before awarding contract, letter of intent will be issued to the successful bidder/firms.
10.	After issuance of intent letter the supplier / bidder will submit integrity pact + contract agreement + Safe Guard Certificate on stamp paper Rs.100 each, after which award letter will be issued.
11.	The contractor/supplier will submit correct postal address with land line telephone number, Cell Number and E-mail address.
12.	Technical brochures /Literature of quoted brand, country of origin of quoted item/material may be attached with the bid as and where applicable. However, in case any such clarification regarding item/s is needed, the committee (Technical/ Financial) reserves the right to get such clarification in writing from the bidder.
13.	Supplier will attach all relevant papers/check list (Active GST certificate, Active NTN, Active Drug Manufacturing license, Drug Sale license, valid distribution certificate & Price list of quoted items etc) as asked for with the bid as documentary evidence. Each page should be signed and stamped by the bidder.
14.	If a bidder withdraws his bid during the period of bid validity, his case will be decided as per PPRA rules.
15.	Contractor/Supplier will sign and stamp each page of tender schedule.
16.	If there is any discrepancy found between the following: A. unit price& total price B. total & sub total price C. amounts in figures & words D. grand total of price schedule & amount mentioned on the bid forms The case will be finalized as per PPRA bidding documents.

17.	The bidder will attach Quality testing report of quoted product from Drug Testing Laboratory or any international ISO certified laboratory within last 03 years.
18.	The bidder should mention the brand/s with generic name in the prescribed column according to FGPC tender schedule.
19.	**The sample(s) of items has to be presented by bidder for verification of specifications/technical evaluation.** a. The committee is authorized to approve a product without sample presentation if not required by virtue of its well-known brand name. b. The committee reserves the right to reject a product if bidder is unable to present the sample if desired.
20.	Bids are to be submitted by the Pharmaceutical Manufacturing Units, Marketing Authorization Holder/Importer/ Indenter (Sole Agents in case of imported drugs) and Authorized Distributors. In case of imported product, the documents of sole agent for Pakistan, duly verified from the country of origin shall be required.
21.	After submission of bid/s, the bidder cannot request for any change in the price of the A/Unit or the size of the packing or change in the content of the bid/s. Any request will make the bid of that item liable to rejection with exclusion of that item (s) from the competition. Any increase in market price will be borne by the bidder. However in case of any decrease in the market price (as fixed by the DRAP), the firm will be responsible to revise their price according to DRAP.
22.	The bidder should submit an **UNDERTAKING ON JUDICIAL PAPER**, that the price quoted in the tender for the items of same specification; quality /brand etc are not more than the price charged from any other public sector hospital in Islamabad under same terms & conditions. In case of any discrepancy, the bidder will refund the excess amount or excess amount will be deducted from the outstanding bills/CDR.
23.	Undertaking on stamp paper stating that the company shall ensure supply of bar coded items (for tracing and tracking the product and company, where applicable)
24.	The companies should exist on IMS data and should submit documentary proof.
25.	The bidder shall submit the documentary proof (Purchase Order) of last 05 (five) years for supplies made to Government Hospitals/ Government Departments/ Tertiary Care Hospital/ International Donor Agencies.
26.	The quoted rate in tender schedule will be final, and no change therein will be accepted after opening of tender.
27.	The Vendor/Firm will submit the documents in support of tender requirements. In case any vendor submits any forged documents, which are proved at any stage to be wrong, the vendor would be dealt with as per PPRA Rules regarding blacklisting/debarment.
28.	**BID VALIDITY IS 180 DAYS** from the date of opening of the tender.
29.	**In case of any dispute/ Relaxation, the Executive Director FGPC will be the final authority.**
30.	The Executive Director FGPC reserves the right to accept or reject any tender/all tenders without assigning any reason according to PPRA Rules.

B. GENERAL CONDITION

1.	This contract is valid for the financial year 2025-26 (extendable) from the date of commencement & will remain in-force till the finalization of new contract. However, the contract will be extended on the same terms and conditions as per PPRA Rules.
2.	The successful bidder will be awarded contract after submission of CDR @ 5**% (performance guarantee)**, agreement on stamp paper, safe guard certificate and undertaking on judicial paper that he agrees to supply the items regularly on approved rates for whole contract period.
3.	The procuring agency reserves the right, at the time of contract award, to increase or decrease the quantity of related products originally specified in the Schedule of Requirements, provided that such variation does not exceed the percentage indicated in the **Bid Data Sheet (BDS)**. This adjustment shall be made without any change in the unit price or other terms and conditions of the Bids and Bidding Documents.
4.	**The Bidder/supplier will quote rates inclusive of taxes. All government taxes will be applicable as per rule/policy. Income/Sales tax will be deducted /charged from the payment of vendor**

	according to Government rules, at source.
5.	All Drug/Medicines/items will be received on FOR basis, FGPC Islamabad.
6.	The supplies must be made **within 40 days** after the issuance of supply order.
7.	The tentative quantities are mentioned in the tender documents, however the subject quantities may vary according to the actual need/requirement of the Institute.
8.	The change of distributor during whole year and change in approved brand is not allowed. However, if DRAP approves any changes in its packing or any other specifications, in such case competent authority i.e Executive Director reserves the right to make decision regarding acceptance/rejection of these change/s. However firm will be responsible to provide the documents of DRAP regarding all such changes.
9.	If vendor fails to supply the items within stipulated period, purchases will be made from alternate source, the risk and cost of which will be borne by the vendor.
10.	If the vendor continually fails/ Non-compliance of supply orders i.e more than Three times, then the matter will be referred to the financial committee for the recommendations of 2nd lowest price bidder and action against suchnon-supplier will be taken as per PPRA rules.
11.	In case of any discrepancy & conflict in submitted online data of application and hard copy of application, the data submitted on EPADS of PPRA will be considered final.

C. SPECIFIC TERMS & CONDITIONS.

1.	The item/s shall be accompanied by the necessary warranty in accordance with the provision of the Drugs Act 1976 & DRAP act 2012 and rules framed therein if applicable. The warranty shall be supplied at the time of delivery of consignment
2.	Bill of the supplies will be submitted with the supply/delivery challan and original supply order within 15 days. For late submission of bills, institute will not be responsible for delay in payment.
3.	Prices of items should not be more than the ratesapproved by DRAP. In case of violation, the amount exceeding the DRAP approved rates/price will be deducted from the outstanding bills/CDR of the supplier.
4.	The payment will be made after the satisfactory report of the store authorities.
5.	The approved rates will be valid for the whole contract period and there will be no increase in rates and no escalation clause.
6.	Prices of drugs should not be more than those approved by DRAP. Documentary proof (Printed price lists) should be submitted along with the tender.
7.	Medicinal products that are supplied in vials, bottles and containers must have sealed caps.
8.	All durgs/medicine will be supplied with appropriate packing according to Drug Act 1976 & DRAP Act 2012.
9.	During the financial evaluation, if the quoted rates of any item have ties between the two or more bidders, then the case may be decided as per PPRA Rules.
10.	Thermo labile items like Vaccines, Sera, Insulin, Ophthalmic preparations and infusions will be supplied under specific storage conditions and the supplier shall be responsible to maintain the cold chain, failing which the delivery will not be accepted and the Hospital will not be responsible for any inconvenience caused thereof.
11.	The contractor/supplier will supply the item (s) according to the specifications as laid down in the tender schedule.
12.	The purchase order may be cancelled by the competent authority at any time, as well as quantity may be increased / decreased without assigning any reason.
13.	In case of short/near expiry of drugs/medicines, the supplier shall have to replace the stock with long expiry batch, three months before the date of expiry of previous stock. In case, any drug/medicine expires in store, the said item/s will be destroyed by the nominated committee according to drug act 1976 & DRAP Act 2012. The vendor will be bound to provide replacement of expired item/s OR to deposit the value of expired item/s into Government Treasury OR the amount will be deducted from pending bills/ CDR.
14.	No drug shall be accepted having expiry date of original shelf life less than 75% of locally manufactured & 60% of imported item/s.

	In case of desperate need of drug in unusual circumstances the competent authority (Executive Director) reserves the right to permit the supply of drug in hospital. However, the supplier shall pay a penalty equal to **1%** of the total value of the medicine/item per percentage point of the short fall in the prescribed shelf life, which is 75% for the locally manufactured and 60% for the imported item/s. In case of life saving drug being short/not available in open market, the case will be decided by the competent authority i.e Executive Director irrespective of its shelf life giving a priority to its duration of utilization and according to its clinical turnover, with same penalty applied as mentioned above. Manufacturing and expiry date will be written on each pack and without these dates no supply will be accepted.
15.	The earnest money against approved items will not be released till completion of tender i.e. **30-06-2026**, which shall remain extendable by the Executive Director till finalization of next such tenders. However, such extension will be made under same term & conditions.
16.	At any instance, if prices quoted/offered are found higher than price approved by the Drug Regulatory Authority of Pakistan (DRAP), disciplinary action will be initiated, the contract be cancelled and earnest money will be forfeited.
17.	Drugs/medicines should be DRAP registered.
18.	The freight charges will be borne by the suppliers.

D. RESPONSIBILITIES.

01.	In case of any discrepancy like less weight, short supply etc, the supplier and concerned store department will be held responsible.
02.	All drug/medicines supplied will be in accordance with the Drugs Act 1976& DRAP Act 2012 "Labeling and packaging rules".
03.	The words "**NOT FOR SALE, FOR FGPC USE ONLY"** in form of insignia (Large size) should be printed with undeletable ink in bold letter on each outer packing and inner packing , if any
04.	Packing should be worthy of transportation by Road, Sea, or mail as to ensure their contents being free from loss or damage due to faulty packing.
05.	The expenditure involved on test/analysis of medicine shall be borne by the manufacturer/supplier of the medicine.
06.	In case of short/near expiry of drugs/medicines, the supplier shall have to replace the stock with long expiry batch, three months before the date of expiry of previous stock. In case, any drug/medicine expires in store, the said item/s will be destroyed by the nominated committee according to drug act 1976 & DRAP Act 2012. The vendor will be bound to provide replacement of expired item/s OR to deposit the value of expired item/s into Government Treasury OR the amount will be deducted from pending bills/ CDR.
07	No drug shall be accepted having expiry date of original shelf life less than 75% of locally manufactured & 60% of imported item/s. In case of desperate need of drug in unusual circumstances the competent authority (Executive Director) reserves the right to permit the supply of drug in hospital. However, the supplier shall pay a penalty equal to **1%** of the total value of the medicine/item per percentage point of the short fall in the prescribed shelf life, which is 75% for the locally manufactured and 60% for the imported item/s. In case of life saving drug being short/not available in open market, the case will be decided by the competent authority i.e Executive Director irrespective of its shelf life giving a priority to its duration of utilization and according to its clinical turnover, with same penalty applied as mentioned above. Manufacturing and expiry date will be written on each pack and without these dates no supply will be accepted. Warranty for quality of item/s shall have to be provided at the time of delivery of stock.
08	Manufacturing and expiry date will be written on each pack and without these dates no supply will be accepted.

E. FORCE MAJEURE.

01.	For the purposes of this clause Force Majeure means an act of God or an event beyond the control of the supplier and not involving the supplier's fault or negligence directly or indirectly purporting to miss planning, miss management and/or lack of foresight to handle the situation. Such events may include but are not restricted to acts of the purchaser in its sovereign capacity, wars or revolutions, fires, floods, earthquakes, epidemics, quarantine restrictions and freight embargoes. If a Force Majeure situation arises, the supplier shall promptly notify the purchaser in writing with sufficient and valid evidence of such condition and the cause thereof. The Force Majeure Committee will examine the pros and cons of the case and all reasonable alternative means for completion of supply order under this Contract and will submit its recommendations to the competent authority. However, unless otherwise directed by the purchaser in writing, the supplier shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek reasonable alternative means for performance not prevented by the Force Majeure event.

F. PENALTIES.

01.	Test/analysis of item/s from Government Drug Testing Laboratory will be done according to the prescribed procedure as per Drug Act, 1976 & DRAP Act 2012. If item/s is found substandard, adulterated etc., the same will not be returned to the supplier and will be seized or destroyed by the nominated committee. The payment of defective/batch/item/s will not be made to the supplier. The supplier will be responsible to provide the fresh stock of standard quality against the confiscated stock **within 30 days** equivalentto the quantity or amount of defective Drugs/items, the payment of which will be deducted from the bills/CDR of the firm. The case will be dealt as per Drug Act, 1976 & DRAP Act 2012 and rules framed therein.
02.	In case of short/near expiry of drugs/medicines, the supplier shall have to replace the stock with long expiry batch, three months before the date of expiry of previous stock. In case, any drug/medicine expires in store, the said item/s will be destroyed by the nominated committee according to drug act 1976 & DRAP Act 2012. The vendor will be bound to provide replacement of expired item/s OR to deposit the value of expired item/s into Government Treasury OR the amount will be deducted from pending bills/ CDR.
03.	No drug shall be accepted having expiry date of original shelf life less than 75% of locally manufactured & 60% of imported item/s. In case of desperate need of drug in unusual circumstances the competent authority (Executive Director) reserves the right to permit the supply of drug in hospital. However, the supplier shall pay a penalty equal to **1%** of the total value of the medicine/item per percentage point of the short fall in the prescribed shelf life, which is 75% for the locally manufactured and 60% for the imported item/s. In case of life saving drug being short/not available in open market, the case will be decided by the competent authority i.e Executive Director irrespective of its shelf life giving a priority to its duration of utilization and according to its clinical turnover, with same penalty applied as mentioned above. Manufacturing and expiry date will be written on each pack and without these dates no supply will be accepted. Warranty for quality of item/s shall have to be provided at the time of delivery of stock.
04.	At any instance, if quoted prices are found higher than price approved by the Drug Regulatory Authority (DRAP), the Institute has the right to impose penalty decided by the competent authorityaccording to PPRA rules.
05.	In case of repeated delay in services or short fall in supplies, the contract is liable to penalty as per penalties clause No 08& 09.
06.	In case of failure in supply within prescribed period of **40 days**, the bidder must request the hospital for extension of period of delivery with clear reasons.
07.	The supplier, once awarded product, will be responsible to keep a contact with the organization for supply, within due time. Failure to respond to officially conveyed demand (in writing on given address/ authorized person/ Telephone Number or E-mail) will be considered noncompliance to the supply order as per preceding clause.

08	In case, non-supply/ short supply is established against a firm beyond **40 days** (from supply order) and **final notice for 15 days**, the risk purchase will be made at the cost of supplier and amount of risk purchase will be deducted from the pending bill of supplier/CDR. The matter may also be referred to Financial Committee for cancellation of said item/s and selection of bidder with 2nd lowest price, from bids received in original tender as per PPRA Rules, 2004.
09	**Non-compliance of supply order**. If the supply order is not completed **within stipulated period (40 days)** one or more of the following penalties can be applied against the firm according to the gravity of situation as per PPRA Rules. a. A penalty **@ 0.1%** per day of the amount of pending item (s) of the supply order shall be imposed. b. Risk purchase will be made at the cost of supplier and amount will be deducted from the bills of supplier. c. The matter will also be referred to Procurement committee (Financial) for cancellation of said items and selection of bidder with 2nd lowest price from bids received in original tender as per PPRA Rules, 2004. d. The contract of the supplier will be treated as cancelled and the order for supply of item (s) will be placed to the next lowest. e. Total or partial earnest money (CDR) will be forfeited. f. The firm will be debarred for business at FGPC as per PPRA rules. g. The firm will be blacklisted as per PPRA Rules. h. In case of any complaint about the penalty(s) imposed on the firm, the firm can appeal against the decision in the **Grievance Redressel Committee within 15** days of the issue of penalty(s) letter. After the lapse of this period no appeal will be entertained.

G. ARBITRATION AND RESOLUTION OF DISPUTES:-

1	The purchaser and the supplier shall make every effort to resolve amicably any disagreement or dispute arising between them under or in connection with the contract by direct informal negotiation.
2	If, after **thirty (30) days** from the commencement of such informal negotiation, the purchaser and the supplier have been unable to resolve amicably a contract dispute, either party may refer the dispute to the Arbitrator for resolution through arbitration.
3	In such matters, the Arbitrator shall be appointed and will be agreed upon by both parties.

Note: - If at any point in time, any part of this document is found to be different/in contradiction with PPRA rules, the ruling mentioned in PPRA Rules will be considered final.

EXECUTIVE DIRECTOR

I/We have read and agree with the above mentioned terms and conditions.

Name & Stamp of firm Proprietor _____

Witness:-

Name and Signature: - _____

NIC No: - _____

Cell No. _____

FEDERAL GOVERNMENT POLYCLINIC
(Postgraduate Medical Institution)
ISLAMABAD

LIST OF DRUG/MEDICINE FOR THE FINANCIAL YEAR 2025-26

I.D. NO.	GENERIC NAME	STRENGTH	DOSAGE FORM
	Anaesthesia & ICU		
1	Atracurium Besylate 3ml	10mg/ml	Ampoules
2	Atropine Sulphate 1 ml	1000 mcg / ml	Ampoules
3	Bupivacaine HCl 0.5% (10 ml)	5 mg / ml	Ampoules
4	Epinephrine (as HCl)	1 mg / ml	Ampoules
5	Flumazenil	0.10%	Vials
6	Glycopyrolate +Neostigmine Methylsulphate 1 ml	0.5 mg + 2.5mg	Ampoules
7	Glycopyrrolate 1 ml	0.2 mg / ml	Ampoules
8	Lignocaine HCL (2% w/v) 10 ml, I/V	20 mg	Ampoules
9	Lignocaine HCL + Adrenaline 2% (10 ml)	1:200000	Ampoules
10	Midazolam (as HCl) 5 ml	1 mg / ml	Ampoules
11	Nalbuphine HCL 1 ml	10 mg / ml	Ampoules
12	Norepinephrine acid tartarate 4ml	1mg /1ml	Ampoules
13	Propofol 1% (20 ml)	10 mg / ml	Infusion
14	Propofol with MCT/LCT	20 ml	Infusion
15	Suxamethonium Chloride 2ml	50 mg / ml	Ampoules
16	Isoflurane Inhalation	100ml	Solution
17	Sevoflurane	250ml	Solution
18	Glyceryl Trintrete (GTN 100mg/1.0ml (10ml)	1mg/ml	Ampoules
19	Ketamine 10ml	50mg/ml	Ampoules
20	Dexmedetomidine 2ml	100mcg/ml	Ampoules
21	Lignocaine HCl	15gm	Gel
	Cardiology		
22	Adenosine	6mg	Injection
23	Adrenaline inj	1mg/ml	Ampoules
24	Amiodarone	150 mg	Ampoules
25	Amlodipine + Valsartan	5 mg + 80mg	Tablet
26	Amlodipine Besylate	5 mg	Tablet
27	Aspirin enteric coated	75 mg	Tablet
28	Bisoprolol Fumarate	5 mg	Tablet
29	Calcium Gluconate 10ml	100mg	injection
30	Captopril	25 mg	Tablet
31	Clopidogrel (Film Coated)	75 mg	Tablet
32	Digoxin	250mcg	Tablet
33	Digoxin i.v	500mcg	Ampoules
34	Diltiazem HCl	90 mg	Capsules
35	Sotalol	80mg	Tablet
36	Enoxaparin	60 mg	Ampoules
37	Furosemide	40 mg	Tablet
38	Furosemide	20 mg / 2 ml	Ampoules
39	Furosemide + Spironolactone	40 mg + 50mg	Tablet
40	Indapamide	0.5mg	Tablet
41	Heparin 5ml	5000 IU/ml	Vials
42	Isosorbide Dinitrate 10 ml	10 mg	Ampoules
43	Labetalol	100mg	Tablet
44	Labetalol	100mg	Injection
45	Losartan Potassium	50 mg	Tablet

46	Methyldopa	250 mg	Tablet
47	Metoprolol Tartrate	5mg	Injection
48	Nifedipine LA	30 mg	Tablet
49	Rosuvastatin	10 mg	Tablet
50	Saccubutril+ Valsartan	50mg	Tablet
51	Spironolactone	100mg	Tablet
52	Streptokinase	1.5 MIU	Vials
53	Trimetazidine	35mg	Tablet
54	Verapamil	5mg	Injection
55	Warfarin	5 mg	Tablet
56	Propanolol	10mg	Tablet
57	Losartan + Hydrochloro thrazide (HTN)	50/12.5mg	Tablet
58	Lisinopril	5mg	Tablet
59	Ivabradine	5mg	Tablet
60	Ranolazine	500mg	Tablet
61	Isosorbide Mononitrates	20mg	Tablet
62	Glyteryl trinitrate	2.6mg	Tablet
63	Hydralazine	50mg	Tablet
64	Nebivolol	5mg	Tablet
65	Doxazocin	2mg	Tablet
66	Amiodarone	200mg	Tablet
67	Amlidipine + Valsartan +Hydrochlorthiazide	5/160/12.5mg	Tablet
68	Ticagrelor	90mg	Tablet
69	Rosuvastatin	10mg	Tablet
70	Apixaban	5mg	Tablet
71	Milrinone	10mg	Infusion
72	Norepinephrine	2mg	Injection
73	Norepinephrine	4mg	Injection
74	Flecainide	50mg	Tablet
75	Gemfibrozil	600mg	Tablet
76	Fenofibrate	200mg	Tablet
77	Rosuvastatin + Ezitimibe	10mg + 10mg	Tablet
78	Perindopril	4mg	Tablet
	Diabetis/Endocrine		
79	Carbimazole	5mg	Tablet
80	Gliclazide MR	60 mg	Tablet
81	Glimipride	2 mg	Tablet
82	Insulin Glargine	100 iu / ml	Vial
83	Insulin NPH (Isophane Human)	100 iu / ml	Vial
84	Insulin Regular (Insulin Soluble Human)	100 iu / ml	Vial
85	Metformin	500 mg	Tablet
86	Sitagliptin + Metformin hydrochloride	50 mg + 1000mg	Tablet
87	Sitagliptin + Metformin hydrochloride	50 mg + 500mg	Tablet
88	Soluble Insulin + Isophane Humulin	(70% + 30%) 100 iu / ml	Vial
89	Hydrocortisone	100mg	Tablet
90	Levothyroxine Sodium / Thyroxine sodium anhydrous	50 mcg	Tablet
91	Fludrocortisone	0.1mg	Tablet
92	Bromocriptine	2.5mg	Tablet

93	Conjugated Estrogen	0.3	Tablet
94	Estradiol Valerate/ Norgestrel	2mg/0.5mg	Tablet
95	Estradiol Valerate	2mg	Tablet
96	Ethinyl Estridiol/ Cyproteeone Acetate	0.035mg/2mg	Tablet
97	Empagliflozin	10mg	Tablet
98	Empagliflozin	25mg	Tablet
99	Glibemclamide	5mg	Tablet
	Dental Surgery		
100	Lignocaine Plain 2% (1.8 ml)	1.8 ml	Dental Cartridge
101	Lignocaine with adrenaline 2% (1.8 ml)	1.8 ml	Dental Cartridge
	Dermatology		
102	Betamethasonen valerate 0.1%	15 Gm	Ointment
103	Clobetasol Propionate 0.05%	10 Gm	Cream
104	Clotrimazole + +Hydrocortisone 10 Gm	1%	Cream
105	Cyproterone + Ethinyl Estradiol	2 mg + 35mcg	Tablet
106	Fusidic acid 2%	15 Gm	Cream
107	Methyl prednisolone aceponate 0.1%	5 Gm	Cream
108	Methylprednisolone sodium Succinate	1 Gm	Vials
109	Permethrine 5%	10 Gm	Cream
110	Polymyxin B+Bacitracin zinc	10 Gm	Ointment
111	Prednisolone	5 mg	Tablet
112	Terbinafine	125 mg	Tablet
113	Clindamycine	1%	Lotion
114	Cetrizine	10mg	Tablet
115	Chlorpheniramin	4mg	Tablet
116	Chlorpheniramin	2mg/5ml	Syrup
117	Acyclovir	400mg	Tablet
118	Isoconazole 1%	10gm	Cream
	ENT		
119	Azithromycine (as dihydrate) 15 ml	200 mg	Suspension
120	Betahistine dihydrochloride	16 mg	Tablet
121	Bethmethasone sodphos+Neomy.sul (E/E)	5 ml	Drops
122	Chlorpheniramine Maleate	4 mg	Tablet
123	Chlorpheniramine Maleate 120 ml	2 mg / 5 ml	Syrup
124	Flunesuliode (Nasal)	15 ml	Spray
125	Fluticasone furoate (Nasal)	27.5 mg / 120doses	Spray
126	Nystatin 30 ml	100000 IU	Drops
127	Ofloxacin 0.6% (Ear)	5 ml	Drops
128	Promethazine HCl Elixir	5 mg / 5 ml	Syrup
129	Sodium Cromoglycate +Xylometazoline HCl (Nasal)	15 ml	Spray
130	Xylometazoline 0.10% (Nasal)	20 ml	Spray
	Eye		
131	Brimonidine Tartrate 0.2% (Eye)	5 ml	Drops
132	Ciprofloxacin 0.3% (Eye)	5 ml	Drops
133	Fluorometholone 1% (Eye)	5 ml	Drops
134	Moxifloxacin + Dexamethasone (Eye)	5 ml	Drops
135	Nepafenac (Eye) 0.1%	5 ml	Drops
136	Prednisolon acetate + Sulphacetamid (Eye)	5 ml	Drops
137	Prednisolone 0.2% (Eye)	5 ml	Drops
138	Tobramycin (Eye)	5 ml	Drops

139	Travoprost 0.0041% (Eye)	2.5 ml	Drops
140	Betaxolol 0.25%	5ml	Drops
141	Tobramycin + Dexamethsone eye Ointment	10gm	Ointment
142	Tobramycin +Dexamethsone eye Drops	5 ml	Drops
143	Timolol +Dorzolamide eye drops	5 ml	Drops
144	Olopatadine eye drop	5 ml	Drops
	Liver Clinic		
145	Tenefovir	300mg	Tablet
146	Sofosbuvir+ Velpatasvir	400mg+ 100mg	Tablet
	Gynae & Obstt.		
147	Anti-D Immunoglobulin	300 mcg	Vials
148	Clotrimazole, Vaginal	500 mg	Tablet
149	Clotrimazole, Vaginal 5Gm	10%	Cream
150	Dinoprostone, Vaginal	3 mg	Tablet
151	Dydrogesterone	10 mg	Tablet
152	Estradiol valerate + Norgestrel	2 mg + 0.5 mg	Tablet
153	Hydroxyprogesterone Caproate Depot 1 ml	250 mg	Ampoules
154	Iron and vitamins with folic acid (Strip pack)		Spansules
155	Iron Sucrose 5 ml	100 mg	Ampoules
156	Misoprostol	200 mcg	Tablet
157	Norethisterone	5 mg	Tablet
158	Nystatin + Polymyxin B +neomycin	100000 IU +35000 IU + 35000 IU	Vaginal Capsules / Tablet
159	Oxytocin	5iu	Infusion
160	Sulfathiazole +Sulfucetamide + Sulfabenzamide + Urea (Vaginal)	3.42% + 2.86% + 3.7% + 0.64 %	Cream
	Medicine &ICU		
161	Omeprazole	20 mg	Capsule
162	Omeprazole	40 mg	Infusion
163	Acetaminophen	500 mg	Tablet
164	Acetaminophen Infusion (100 ml)	1 Gm	Infusion
165	Acyclovir	400 mg	Tablet
166	Acyclovir	1000 mg	Infusion
167	Acyclovir 5%	10 gm	Cream
168	Alprazolam	0.5 mg	Tablet
169	Amikacin (as Sulphate) 2ml	100 mg	Ampoules
170	Amoxycillin as Sodium salt	500 mg	Vials
171	amoxycilline as trihydrate	500mg	Capsules
172	Artemether + Lumefantrine	80 mg + 480 mg	Tablet
173	Azithromycin	500mg	Tablet
174	Azithromycin	500mg	Injection
175	Beclomethasone dipropionate 2ml (Sol)	800 mcg / 2 ml	Nebule
176	Cefixime	400 mg	Capsules
177	Cefotaxime	1 Gm	Vials
178	Ceftriaxone	1 Gm	Vials
179	Cephradine	500 mg	Vials
180	Cephradine	500 mg	Capsules
181	Chloroquine Phosphate	250 mg	Tablet
182	chlorpheniramine Maleate + Terpin hydrate + Amonium choloride + aminophylline 120ml	5+10+25+32/5ml	Syrup
183	Chlorpromazine 2 ml	25 mg	Ampoules
184	Ciprofloxacin	500 mg	Tablet

185	Ciprofloxacin	200mg	Infusion
186	Clavulanic acid+Amoxycillin Trihydate	1.2 Gm	Vial
187	Clavulanic acid+Amoxycillin Trihydate	625 mg	Tablet
188	Desferrioxamine Mesylate	500 mg	Vials
189	Dimenhydrinate	50 mg	Tablet
190	Dimenhydrinate 1 ml	50 mg / ml	Ampoules
191	Dimenhydrinate 60 ml	12.5 mg / 4 ml	Liquid
192	Divalporic Sodium 5 ml	500 mg	Ampoules
193	Dobutamine	250 mg	Infusion
194	Domperidone	10 mg	Tablet
195	Dopamine 5 ml	200 mg	Ampoules
196	Doxycycline (as hyclate)	100 mg	Capsules
197	Fluticasone Propionate 120 actuations	100 mcg	Inhaler
198	Gentamycin sulphate 2 ml	80 mg	Ampoules
199	Human Albumin 20%	100 ml	Infusion
200	Human Immunoglobulin	10 ml	Vials
201	Human Immunoglobulin	50 ml	Vials
202	Imipenem (as Monohydrate) + Cilastatin as (Na Salt)	500 mg	Vials
203	Ipratropium Bromide (as the monohydrate)	500 mcg / 2 ml	
204	Ipratropium Bromide (Aerosol)	20 mcg / inhalation	pressurized Aerosol
205	Lactulose 120ml	3.35 gm / 5 ml	Suspension
206	Moxifloxacin	400mg	Tablet
207	Linezolid	600mg	Infusion
208	Magnesium trisilicate + aluminium hydroxide	250 mg + 120mg	Tablet
209	Mebendazole	100 mg	Tablet
210	Mefenamic acid	500 mg	Tablet
211	Meropenem	1 Gm	Vials
212	Meropenem	500 mg	Vials
213	Montelukast Sodium	10 mg	Tablet
214	Montelukast Sodium Powder	4 mg	Sachet
215	Moxifloxacin (as HCl) 250ml	400 mg	Infusion
216	Naloxone HCL 1 ml	0.4 mg	Vials
217	Octreotide acetate 1 ml	0.5mg	Ampoules
218	Pheneramine Maleate 2ml	22.7 mg / 2 ml	Ampoules
219	Piperacillin + Tazobactam	4 Gm + 500 mg	Vials
220	Pralidoxime Methylsulphate	200 mg / 10 ml	Ampoules
221	Promethazine HCl 2 ml	25 mg / ml	Ampoules
222	Protamine Sulphate 5 ml	1000 IU	Ampoules
223	Pyridoxine HCl	50 mg	Tablet
224	Salbutamol 200 doses	100mcg	Inhalor
225	Salbutamol	0.5% w/v	Solution
226	Salbutamol Sulphate 1 ml	0.5 mg / ml	Ampoules
227	Salmterol Xinafoate + Fluticasone Propionate (CFC Free) 120 actuations	50 mcg + 500 mcg	Evohalor
228	Streptomycin	1 Gm	Vials
229	Terlipressin	1mg	Injection
230	Tetracycline	250 mg	Capsules
231	Tigecycline	50 mg	Vials
232	Tobramycin Sulphate 1 ml	10 mg	Ampoules
233	Vancomycin HCl 10 ml	1gm	Vials
234	Vitamin-K 1 ml	10 mg	Ampoules
235	Benzathine Pencilline	12mg	Injection

236	Colistimethate sodium	2MIU	injection
237	Vitamin B1, B6, B12	Vit-B. complex	Injection
	Nephrology		
238	Allopurinol	100 mg	Tablet
239	Azathioprine	50 mg	Tablet
240	Calcium acetate	667mg	Capsules
241	Erythropoietin alpha	2,000 I.U	Vials
242	Erythropoietin beta	5,000 I.U	Vials
243	Sodium acid citrate	120 ml	Liquid
244	Alfacalcidol	0.5mg	Tablet
245	Methylprednisolone sodium Succinate	500mg	injection
246	Sodium Bicarbonate	300mg	Tablet
247	Sevelamer Carbonate	400mg	Tablet
248	Tacrolimus	1mg	Tablet/Caps
249	Valsartan	80mg	Tablet
250	Prednisolone E.C	5mg	Tablet
251	Lignocain	2%	Injection
252	Sodium Bicarbonate	50ml	Injection
253	Ferric carboxymaltose 8.4%	500mg	Injection
254	Nefedipine SR	30mg	Tablet
255	Mycophenolate Moftil	500mg	Tablet
	Neurology		
256	Duloxetine HCl	30 mg	Capsules
257	Duloxetine HCl	20 mg	Capsules
258	Lamotrigine	25 mg	Tablet
259	Levetiracetam	500 mg	Tablet
260	Mecobalamine	500 mcg	Tablet
261	Mecobalamine	500 mcg / ml	Injection
262	Multivitamin with minerals	MVT	Tablet
263	Pregabalin	50mg	Tablet
264	Pregabalin	25mg	Tablet
265	Bromazepam	3mg	Tablet
266	Metoclopramide	10mg	Tablet
267	Topiramate	25mg	Tablet
268	Carbamazepine	200mg	Tablet
269	Sodium Divalroex	500mg	Tablet
270	Lacosamide	50mg	Tablet
271	Propronolol Hydrouloride	10mg	Tablet
272	Cabidopa/Levodopa	25/250mg	Tablet
273	Cabidopa/Levodopa	25/100mg	Tablet
274	Ropinirole	0.25mg	Tablet
275	Amantodine	100mg	Tablet
276	Pyridostigmine	60mg	Tablet
277	Amitryptaline	25mg	Tablet
278	Qvetiapine	25mg	Tablet
279	Clonazepam	0.5mg	Tablet
280	Flunarizine	10mg	Tablet
281	Prochlorperazine	5mg	Tablet

282	Zolmitriptan	2.5mg	Tablet
283	Memantine	10mg	Tablet
284	Tizanidine	2mg	Tablet
285	Rivastigmine	10mg	Tablet
286	Acetazalomide AZM	250mg	Tablet
287	Baclofen	10mg	Tablet
	Paediatrics		
288	Acetaminophen 120 ml	120 mg/5ml	Suspension
289	Acetaminophen drops (20ml)	60 mg / ml	Drops
290	Albendazole 10 ml	100 mg / 5 ml	Suspension
291	Amoxycillin as Trihydrate 90 ml	250 mg	Suspension
292	Artemether + Lumefantrine	60 ml	Suspension
293	Beractant 4 ml	25 mg / ml	Vials
294	Calcium with Vit-D	60 ml	Suspension
295	Cefixime 30 ml	200 mg / 5 ml	Suspension
296	Cephradine 60 ml	250 mg / 5 ml	Suspension
297	Metronidazole (60 ml)	200mg/ 5ml	Syrup
298	Clarithromycin 70 ml	250 mg	Suspension
299	Co-Amoxiclave	156.25mg/ 5ml	Syrup
300	Diloxanide Furoate+ Metronidazole	250 mg + 320 mg / 10 ml	Suspension
301	Divalporic Sodium 120 ml	250 mg	Syrup
302	Domperidone (60 ml)	5 mg / 5 ml	Suspension
303	Ibuprofen 90 ml	100 mg	Suspension
304	Iron Polymaltose complex	120 ml	Syrup
305	Multivitamin	60 ml	Syrup
306	Promethazine HCL, Pholcodine,	1.5mg +1.5mg	linctus
307	Trimethoprim + Sulfamethoxazole 50 ml	80 mg + 400 mg / 5 ml	Suspension
308	Zinc sulphate 60 ml	20 mg / 5 ml	Suspension
309	Deferasirox	400mg	Tablet
310	saccharomyces boulardii (Probiotic)	250mg	Sachet
311	Levetiracetam	100mg/ml	Suspension
312	Ciprofloxacin	250/5ml	Suspension
313	Ketotifen	0.2mg/ml	Syrup
314	Cetirizine	5mg/5ml	Syrup
315	Dioctahedral Smectite	03gm	Sachet
316	Carbamazepine	100mg/05ml	Syrup
317	Salmeterol+ Fluticasone propionate	25mcg/50mcg	Inhaler
318	Ondasetron	4mg/5ml	Syrup
319	Terbutaline	0.3mg/ml	Syrup
	Psychiatry		
320	Clonazepam	2 mg	Tablet
321	Diazepam 2ml	10mg	Ampoules
322	Divalporic Sodium	500 mg	Tablet
323	Escitalopram	10 mg	Tablet
324	Fluoxetine hydrochloride	20 mg	Capsules
325	Fluphenazine decanoate 1ml	25 mg	Ampoules
326	Memantine HCl	10 mg	Tablet
327	Olanzapine	10 mg	Tablet

328	Risperidone	2 mg	Tablet
329	Haloperidol	5mg	Injection
330	Serlarine	50mg	tablet
331	Procycline	5mg	Tablet
332	Alprazolam	0.5mg	Tablet
	Rheumatology/ Orthopedics		
333	Diclofenac sodium Gel (1%)	20 gm	Gel
334	Alendronate sodium	70 mg	Tablet
335	Cholecalciferol inj	200000 IU	Ampoules
336	Diclofenac Sodium	50 mg	Tablet
337	Diclofenac Ptassium	50 mg	Tablet
338	Diclofenac Sodium (3 ml)	75 mg	Ampoules
339	Ibuprofen	400 mg	Tablet
340	Leflunomide	20mg	Tablet
341	Ketoralac	30mg	Injection
342	Sodium Fusidate	250mg	Tablet
343	Tizanidine	2mg	Tablet
344	Naproxen sodium	500mg	Tablet
345	Etoricoxib	90mg	tablet
346	Paracetamol + Orphenadrine Citrate	650mg+50mg	Tablet
347	Ketoprofen	50ml	Gel
348	Vita D3 (Calciferol)	5000iu	Capsule
349	Alpha Calceferol	0.5mg	Tablet
350	Calcium Corbonate		Tablet
	Surgery		
351	Antiseptic Healing Cream (for bed sores)	400gm	Cream
352	Cefoperazone + Salbactam	2gm	Injection
353	Diosmin + Hesperidin	450mg + 50mg	Tablet
354	Dexamethasone 1 ml	4 mg / ml	Ampoules
355	Dextrose 5% in Normal Saline with set	500 ml	Infusion
356	Dextrose 5% with electrolytes with set	500 ml	Infusion
357	Dextrose water 10% with set	500 ml	Infusion
358	Dextrose water 5% with set	500 ml	Infusion
359	Dextrose water 25% with set	1000 ml	Infusion
360	Dextrose 5% and 0.45% sodium chloride with set	500 ml	Infusion
361	Drotaverine	80 mg	Tablet
362	Drotaverine 4ml	40mg	injection
363	Fat Emulsion 20%	200mg/5ml	Infusion
364	Hydrocortisone	100 mg	Vials
365	Hydrocortisone	250 mg	Vials
366	IV Sets		Set
367	KCL 7.4%	20 ml	Infusion
368	Levothyroxine Sodium / Thyroxine sodium anhydrous	50 mcg	Tablet
369	Lignocain Haemorrhoidal 5%	20 Gm	Gel
370	Mebeverine HCL	135mg	Tablet
371	Methotrexate	2.5mg	Tablet
372	Metronidazole	400 mg	Tablet
373	Metronidazole (100 ml)	500 mg	Infusion
374	Ondasetron	8mg	Injection

375	Plasma Volume expander	4%	Infusion
376	Polygeline/Plasma substitute 3.5%	500 ml	Infusion
377	Ringer's Lactate with set	500 ml	Infusion
378	Saline 1/5 with set	500 ml	Infusion
379	Silver Sulphadiazine 1%	50 Gm	Cream
380	Sodium Chloride 0.45% and dextrose 5%	500ml	Infusion
381	Sodium Chloride 0.9%	100ml	Infusion
382	Sodium Chloride 0.9% with set	1000 ml	Infusion
383	Sterile water for injection	5 ml	Infusion
384	Aminoacid Solution 5%	500ml	Infusion
385	Tetanus Toxoide (Multi dose)	5 ml	Ampoules
386	Tetanus Toxoide	1 ml	Ampoules
387	Tramadol 1 ml	50 mg / ml	Ampoules
388	Tramadol + paracetamol	37/500mg	Tablet
389	Tranexamic acid	500 mg	Capsules
390	Tranexamic acid 5 ml	500 mg	Ampoules
391	Trypsin + Chymotrypsin 6:1	50000 units	Tablet
392	Pramoxine Hydrochloride	20gm	Ointment
393	GTN 0.2%	0.2%	Cream
394	Mannitol 500ml	20%	Infusion
395	Polyvalent Anti Snake Venom Serum	10 ml	Vials
396	Purified inactivated rabies vaccine	0.5 ml	Vials
	Urology		
397	Solifenacin succinate	10 mg	Tablet
398	Tamsulosin	0.4 mg	Tablet
399	Tamsulosin + Dutasteride	0.4mg+ 0.5mg	Capsule
400	Tolterodine Tartrate	2mg	Tablet
401	Mirabegron	25mg	Tablet
402	Mirabegron	50mg	Tablet